中国组织工程研究

中国组织工程研究 ›› 2011, Vol. 15 ›› Issue (49): 9155-9159.doi: 10.3969/j.issn.1673-8225.2011.49.008

• 脐带脐血干细胞 umbilical cord blood stem cells • 上一篇    下一篇

脐带源与骨髓源干细胞移植治疗神经系统病变的安全性比较

黄  怀1，陈辉强2，庞  妍3，古  菁1，虞容豪1，肖  扬3   

  1. 解放军广州军区广州总医院，1高压氧科，2创伤骨科，3血液科，广东省广州市  510010
  • 收稿日期:2011-03-30 修回日期:2011-05-27 出版日期:2011-12-03 发布日期:2011-12-03
  • 作者简介:黄怀，男，1965年生，江西省樟树市人，汉族，1988年解放军第一军医大学毕业，副主任医师，主要从事神经系统损伤的高压氧及干细胞治疗的临床和基础研究。
  • 基金资助:

    广东省2010年科技计划资助项目(2010B031600264)。

Safety of umbilical cord versus bone marrow-derived mesenchymal stem cells transplantation for the treatment of nervous system lesions

Huang Huai1, Chen Hui-qiang2, Pang Yan3, Gu Jing1, Yu Rong-hao1, Xiao Yang3   

  1. 1Department of Hyperbaricoxygen, 2Department of Traumatic Orthopedics, 3Department of Hematology, Guangzhou General Hospital of Guangzhou Military Command of Chinese PLA, Guangzhou  510010, Guangdong Province, China
  • Received:2011-03-30 Revised:2011-05-27 Online:2011-12-03 Published:2011-12-03
  • About author:Huang Huai, Associate chief physician, Department of Hyperbaricoxygen, Guangzhou General Hospital of Guangzhou Military Command of Chinese PLA, Guangzhou 510010 , Guangdong Province, China huanghuai1999@163.com
  • Supported by:

    the Science and Technology Program of Guangdong Province in 2010, No. 2010B031600264*

PDF

305

被引次数

6

摘要：

背景：对于临床常用于治疗神经系统病变的脐带源干细胞和骨髓源干细胞的安全性，尚无较为全面研究。
目的：比较脐带源和骨髓源干细胞移植治疗神经系统病变的安全性。
方法：将214例神经系统病变患者随机分为两组，分别通过局部、静脉、脑脊液循环途径，移植脐带源干细胞或骨髓源干细胞。每例患者植入干细胞(5~12)×108个。
结果与结论：两组患者干细胞移植治疗后淋巴细胞计数、谷丙转氨酶、谷草转氨酶、IgA、IgM，与治疗前相比有显著性意义(P < 0.01)，组间比较差异无显著性意义(P > 0.05)。两组患者治疗后脑脊液白细胞和红细胞均出现异常，高于正常值，组间比较差异无显著性意义(P > 0.05)。两组患者潘台实验阳性、不良反应发生率组间相比差异无显著性意义(P > 0.05)。说明脐带源和骨髓源干细胞移植治疗神经系统病变的安全性无明显差别。

关键词: 神经系统, 骨髓间充质干细胞, 脐带间充质干细胞, 移植, 安全性

Abstract:

BACKGROUND: The comparative study concerning the safety of umbilical cord and bone marrow-derived mesenchymal stem cells transplantation for the treatment of nervous system lesions is insufficient. 
OBJECTIVE: To assess the safety of umbilical cord and bone marrow-derived mesenchymal stem cells transplantation for treatment of nervous system lesions.
METHODS: A total of 214 cases with neuropathy were randomly divided into A, B groups. Patients in the A group received umbilical cord derived stem cell transplantation, and those in the B group received bone marrow-derived mesenchymal stem cells transplantation. Totally (5-12)×108 stem cells were transplanted into each patient.
RESULTS AND CONCLUSION: The count of lymphocytes, alanine aminotransferase, aspartate aminotransferase, IgA, and IgM were increased compared with those before treatment in both groups (P < 0.01); However there were no significant differences between two groups (P > 0.05). Moreover, white blood cell count and red blood cell count in cerebrospinal fluid of all patients were significantly greater than the normal level. There were no significant differences between two groups (P > 0.05). No significant differences of the positive rate of Pandy test and the incidence rate of adverse effect were found in both groups (P > 0.05). The safety of umbilical cord and bone marrow-derived mesenchymal stem cell transplantation for treatment of nervous system lesions showed no marked differences.

中图分类号: